Literature DB >> 8314290

[Parenteral cephalosporins for the treatment of lower respiratory tract infections].

F Vogel1.   

Abstract

In most cases of respiratory tract infection, antibiotic therapy has to be initiated before the results of microbiological examination are available. The four most common pathogens of acute exacerbations of chronic bronchitis are pneumococci, Haemophilus influenzae, Moraxella catarrhalis and Staphylococcus aureus. Pneumococci are the predominant pathogens of community-acquired pneumonia, followed by H. influenzae and staphylococci. Legionella, mycoplasma and chlamydia vary in frequency according to the population studied. Staphylococci, Pseudomonas, Enterobacter and Klebsiella spp. as well as H. influenzae are the major pathogens of secondary pneumonia. For reasons of cost and environmental problems, oral antibiotics ought to be used whenever possible considering the severity of the infection and patient circumstance. Parenteral antibiotics are indicated in severe infections in order to provide high therapeutic drug levels. Second generation cephalosporins are appropriate for initial therapy of lower respiratory tract infections. In case of severe infection, cephalosporins should be combined with an aminoglycoside, ureidopenicillin or quinolone. Cefuroxime has shown good clinical efficacy and tolerance in lower respiratory tract infections.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8314290     DOI: 10.1007/bf01710341

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  23 in total

Review 1.  [Clinical aspects and diagnosis of community-acquired pneumonia].

Authors:  T Schaberg; H Lode
Journal:  Dtsch Med Wochenschr       Date:  1991-12-06       Impact factor: 0.628

Review 2.  [Comparative studies of the antibacterial effect of so-called basic cephalosporins].

Authors:  G Ruckdeschel
Journal:  Med Klin (Munich)       Date:  1988-12-09

3.  [Therapy with cefotaxime-cefotaxime/ticarcillin for bronchopulmonary infections in patients under intensive care. (author's transl)].

Authors:  C D Schwigon
Journal:  Infection       Date:  1982       Impact factor: 3.553

4.  Randomized study of ceftazidime versus gentamicin plus cefotaxime for infections in severe granulocytopenic patients.

Authors:  B E de Pauw; F Kauw; H Muytjens; K J Williams; T Bothof
Journal:  J Antimicrob Chemother       Date:  1983-07       Impact factor: 5.790

5.  [The arsenal of cephalosporins].

Authors:  W Marget; G Roos
Journal:  MMW Munch Med Wochenschr       Date:  1981-11-06

6.  Community-acquired lower respiratory tract infections. Prevention and cost-control strategies.

Authors:  F M La Force
Journal:  Am J Med       Date:  1985-06-28       Impact factor: 4.965

7.  [Ceftazidime versus cefotaxime in the therapy of severe infections in intensive care patients].

Authors:  E Müller; J Heinkelein
Journal:  Infection       Date:  1987       Impact factor: 3.553

8.  Treatment of skin, skin structure, bone, and joint infections with ceftazidime.

Authors:  L O Gentry
Journal:  Am J Med       Date:  1985-08-09       Impact factor: 4.965

9.  [Microbiological care of ventilated intensive care patients. Feasibility of diagnosis and therapy of pulmonary infection].

Authors:  R Füssle; J Biscoping; D Zeiler; G Michaelis; A Sziegoleit
Journal:  Anaesthesist       Date:  1991-09       Impact factor: 1.041

10.  Comparison of ceftriaxone with cefotaxime in serious chest infections.

Authors:  J H Reeves; G M Russell; J F Cade; M McDonald
Journal:  Chest       Date:  1989-12       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.